



Date: 21st August, 2024

To,
The Manager
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai- 400001

Scrip Code: 544143
BSE Symbol: ROYAL

Subject: Intimation pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 regarding Launch of New Product

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has announced the launch of its new product available for sale from August 21, 2024.

The details of the said product as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated 13th July, 2023, are as follows:

a) Name of the Product	Stergic Chikungunya IgG/IgM Rapid Test
b) Date of Launch	21st August 2024
c) Category of Product	In Vitro Diagnostics
d) Whether caters to domestic and international markets	Caters in Domestic Market

Please take the above information on record and arrange for dissemination.

Yours faithfully,

For Royal Sense Limited

Rishabh Arora
Managing Director
DIN: 09745543

[Stergic Chikungunya IgG/IgM Rapid Test](#)



[Royal Sense Limited is excited to announce the official launch of our latest In Vitro Diagnostics Care Product, the Stergic Chikungunya IgG/IgM Rapid Test detects Chikungunya virus antibodies in blood, providing quick results for diagnosing recent or current infections.](#)

Here are some details you might find in a Stergic Chikungunya IgG/IgM Rapid Test.

The Chikungunya rapid test is a diagnostic tool designed to detect the presence of Chikungunya virus antibodies in a blood sample. This test is typically used to diagnose recent or current infections with Chikungunya virus, which is transmitted by mosquitoes and causes fever, joint pain, and other symptoms. The rapid test works by identifying specific antibodies produced by the immune system in response to the virus. Results are usually available within 15-20 minutes, making it a quick and efficient method for preliminary diagnosis. The test is valuable in areas where Chikungunya is prevalent, allowing for timely medical intervention. It is important to follow up with confirmatory testing and clinical evaluation for accurate diagnosis and treatment.

About Royal Sense Limited: Royal Sense Limited is a leading provider of innovative diagnostic solutions for healthcare professionals worldwide. With a focus on quality, reliability, and accessibility, we are dedicated to improving patient care and advancing the field of medical diagnostics.